Mostly Markets
Subscribe
Markets
S&P 500 ▼ 1.82%Nasdaq ▼ 2.86%Dow ▼ 1.09%Russell 2000 ▼ 1.66%10-year 4.93%Oil ▲ 0.93%Gold ▼ 3.63%Bitcoin ▲ 1.13%
Newest story
Stocks/Health Care/Pharmaceuticals

ViatrisVTRS

Pharmaceuticals · Pittsburgh, Pennsylvania · In the S&P 500
Cheaper than peers
$19.04−0.86%After hours: $18.91 (−0.66%)At the close, 30 Oct · Prices from CNBC, may be delayed
▲ 85.3% over 1 year
Viatris over 1 yearDaily close, $, to 30 Oct 2026
$10$12$15$18Nov2026MarMayJulSep$19.04$10$15NovMarJul$19.04
Source: Nasdaq daily closes
Market value$21.86B
Price to earnings–
Forward P/E7.5x
Dividend yield2.52%
Year to date+52.9%
One year+85.3%
Next earningsThu 5 Nov, before the open
SectorHealth Care
52-week range (closes)
$10.11$19.20

The latest on Viatris

Our stories first, then the headlines that could move it, newest first.

We haven't written about Viatris yet. Follow it, and its first story will show under My stocks.

Quality and valuation

How Viatris compares with other health care stocks. A description, not a recommendation.

Viatris and 4 pharmaceuticals peers. Across: valuation (P/E) against the sector. Up: business quality against the sector. Hover or tap a logo for its numbers.

Business quality: weaker than mostValuation: cheaper than most

A weaker business than most health care companies, priced below most of them.

Viatris trades at 7.5 times the next 12 months of expected earnings, against a median of 19.1x for the 65 health care stocks we cover. The quality score blends where it ranks on revenue growth, gross margin, operating margin and free-cash-flow margin (net margin for banks and insurers) over the last 12 months, from SEC filings.

  • Revenue grew slower than the sector median: +4.5% vs +7.8%
  • Keeps less of each sale (gross margin): 34.9% vs 65.3%
  • Less profitable (operating margin): −0.6% vs 13.3%
  • Turns less of its sales into cash: 13.3% vs 15.9%
VTRS trades at 7.5x forward earnings, below the sector medianForward p/e, Pharmaceuticals peers
VTRS7.5xPFE11.1xNVO12.2xNVS17.0xAZN17.5xMRK18.1xJNJ25.1xLLY36.3xSector median 19.1xVTRS7.5xPFE11.1xNVO12.2xNVS17.0xAZN17.5xMRK18.1xJNJ25.1xLLY36.3xSector median 19.1x
Source: CNBC quotes; Mostly Markets

Financials

From Viatris's SEC filings, through the quarter ending 30 Jun 2026. Hover or tap a bar for its value.

Revenue grew 5.0% from a year earlierQuarterly revenue, $bn, latest Q2 ’26
$0bn$1bn$2bn$3bnQ3 ’24Q1 ’25Q3 ’25$3.8bnQ2 ’26$0bn$2bnQ3 ’24Q1 ’25Q3 ’25$3.8bnQ2 ’26
Source: SEC filings
Growth slowed to +5.0% last quarterRevenue growth, year on year, %
−10%−5%0%5%Q3 ’24Q1 ’25Q3 ’255.0%Q2 ’26−10%0%Q3 ’24Q1 ’25Q3 ’255.0%Q2 ’26
Source: SEC filings
Operating margin was 0.2% last quarterOperating income as a share of revenue, %
−75%−50%−25%0%Q3 ’24Q1 ’25Q3 ’250.2%Q2 ’26−50%0%Q3 ’24Q1 ’25Q3 ’250.2%Q2 ’26
Source: SEC filings
Free cash flow was $2.0 billion over 12 monthsQuarterly free cash flow (operating cash flow minus capex), $m
$0m$200m$400m$600mQ3 ’24Q1 ’25Q3 ’25$329mQ2 ’26$0m$250m$500mQ3 ’24Q1 ’25Q3 ’25$329mQ2 ’26
Source: SEC filings
Last 12 monthsVTRSSector median
Revenue growth+4.5%+7.8%
Gross margin34.9%65.3%
Operating margin−0.6%13.3%
Free cash flow margin13.3%15.9%

Similar companies

Pharmaceuticals, by market value.

CompanyPriceTodayYTDValue
LLYEli Lilly$1,417.54+3.19%+31.9%$1.33T
JNJJohnson & Johnson$273.20−0.73%+32.0%$658B
MRKMerck$149.52+2.18%+42.0%$369B
NVSNovartis$160.79−0.19%+16.6%$327B
AZNAstraZeneca$186.65+7.02%+6.4%$290B
PFEPfizer$30.52+1.90%+22.6%$174B
NVONovo Nordisk$40.00+2.20%−21.4%$136B
BMYBristol Myers Squibb$62.48+1.78%+15.8%$128B